XNAS · Healthcare · Biotechnology
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
iBio's year-end update is strategically better than the headline numbers: it has moved into clinical development with Phase 1 initiation for IBIO-600 and added a new CMO, signaling execution focus in biotech. Financially, the quarter was weak to inline at **-$0.06 EPS** and no revenue versus $66.7k expected, underscoring a still-preclinical, cash-burn story.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-28 | Q4 2026 | -0.06 | -0.06 | +0.00% | $0 | ➖ Inline | +2.14% | — | — |
| 2026-05-12 | Q3 2026 | -0.06 | -0.07 | -16.67% | $0 | ❌ Miss | +2.89% | -6.83% | +3.73% |
| 2026-02-10 |
| Q2 2026 |
| -0.07 |
| -0.09 |
| -28.57% |
| $0 |
| ❌ Miss |
| +5.73% |
| +0.88% |
| +9.69% |
| 2025-11-12 | Q1 2026 | -0.07 | -0.11 | -57.14% | $100,000 | ❌ Miss | — | — | — |
| 2025-09-05 | Q4 2025 | -0.25 | -0.32 | +15.79% | $200,000 | ❌ Miss | — | — | — |
| 2025-02-10 | Q2 2025 | -0.32 | -0.48 | -50.00% | $200,000 | ❌ Miss | -7.31% | +7.60% | +62.28% |
| 2024-09-20 | Q4 2024 | -0.48 | -0.91 | -89.58% | $175,000 | ❌ Miss | -6.09% | +5.58% | +56.85% |
| 2024-05-13 | Q3 2024 | — | -0.71 | — | $0 | — | +3.56% | +18.43% | +40.46% |
Showing last 8 quarters.